*3.7. LABAs*

The latest GINA report recommends treating patients with inadequately controlled asthma with a triple combination of indacaterol acetate/glycopyrronium bromide/ mometasone [1]. Several studies provided evidence that indacaterol maleate is potent and safe in asthmatic patients [75–78].

A Phase I RCT [34,35] compared the efficacy of the maleate salt with the acetate salt of indacaterol 150 μg vs. PCB in patients with asthma. Indacaterol maleate significantly (*p* < 0.001) improved trough FEV1 of 186.0 mL (95%CI 129.0–243.0), FEV1 AUC0-4h by 248.0 mL (95%CI 186.0–310.0), and PEF of 33.0 L/min (95%CI 25.6–40.3) vs. PCB, and it was as effective as indacaterol acetate. No data are available for symptoms control. Rescue medication use was significantly (*p* < 0.01) reduced with both indacaterol salts of 0.42 puffs/day vs. PCB [34,35].
